[Skip to Content]

Upstate Active Clinical Trials

Study Title:

Pilot study of the safety and feasibility of administering concurrent systemic chemotherapy with accelerated hypofractionated radiation therapy in the treatment of medically inoperable T1b and T2 Non-Small Cell Lung Cancer

What is the purpose of the study?

To assess safety and tolerability of concurrent chemotherapy with hypofractionated radiation therapy for T1b, T2a and T2b non-small cell lung cancer. This will serve as a pilot study in designing further trials to compare this to the current standard of care which does not routinely involve systemic chemotherapy for cancer of this stage. The primary endpoint will be to assess the rate of toxicity of the therapy.

Upstate Institutional Review Board (IRB) Number:

665895

Study Phase:

Pilot

Patient Age Group:

Adults

Principal Investigator:

Michael D Mix, MD

What is involved if I participate?

  • What tests and procedures are involved?
    Upstate Cancer Center - all procedures
    The Hill Medical Center - all procedures
    Oswego - all procedures
    Oneida - all procedures

ClinicalTrials.Gov ID:

NCT02619448

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erin Bingham
Phone: 315-464-3603
Email: binghame@upstate.edu

Return to Previous Page || Search Again

Top